Onabotulinum Toxin A (Botox) for Spasticity in Patients With Acquired Brain Injury

No relevant literature was identified regarding the clinical effectiveness or cost-effectiveness of onabotulinum toxin A (Botox) for reducing spasticity in patients with traumatic or non-traumatic–acquired brain injury. Authors of 1 evidence-based guideline recommend the use of botulinum toxin (subtype and formulation not specified) for the treatment of spasticity associated with traumatic brain injury.

Download Full-text

CDC's guideline on pediatric mild traumatic brain injury

Neurology Clinical Practice ◽

10.1212/cpj.0000000000000624 ◽

2019 ◽

Vol 9 (3) ◽

pp. 241-249 ◽

Cited By ~ 2

Author(s):

Barbara Weissman ◽

Madeline Joseph ◽

Gary Gronseth ◽

Kelly Sarmiento ◽

Christopher C. Giza

Keyword(s):

Traumatic Brain Injury ◽

Brain Injury ◽

Mild Traumatic Brain Injury ◽

Pediatric Patients ◽

Young Patients ◽

Evidence Based ◽

Practice Recommendations ◽

Control And Prevention ◽

Evidence Based Guideline ◽

American Academy Of Neurology

Purpose of reviewIn September 2018, the Centers for Disease Control and Prevention (CDC) published an evidence-based guideline on the diagnosis and management of mild traumatic brain injury (mTBI) among children.Recent findingsBased on a systematic review of the evidence that covers research published over a 25-year span (1990–2015), the CDC Pediatric mTBI Guideline strives to optimize the care of pediatric patients with mTBI. The guideline was developed using a rigorous methodology developed by the American Academy of Neurology.SummaryClinical practice recommendations in the CDC Pediatric mTBI Guideline can help guide neurologists with critical diagnostic and management decisions and to implement evidence-based strategies for the recovery of their young patients with this injury.

Download Full-text

Dynamic computerised hand dynamometry: Measuring outcomes following upper limb botulinum toxin-A injections in adults with acquired brain injury

Journal of Rehabilitation Medicine ◽

10.2340/16501977-1781 ◽

2014 ◽

Vol 46 (4) ◽

pp. 314-320 ◽

Cited By ~ 6

Author(s):

H Barden ◽

I Baguley ◽

M Nott ◽

C Chapparo

Keyword(s):

Botulinum Toxin ◽

Brain Injury ◽

Upper Limb ◽

Botulinum Toxin A ◽

Acquired Brain Injury ◽

Toxin A ◽

Measuring Outcomes ◽

Hand Dynamometry

Download Full-text

Vigilance Enhancing Effect of Botulinum Toxin A (Btx A) after Local Application in Vegetative Patients with Severe Spasticity Following Traumatic Brain Injury (TBI)

Functional Rehabilitation in Neurosurgery and Neurotraumatology ◽

10.1007/978-3-7091-6105-0_43 ◽

2002 ◽

pp. 140-140

Author(s):

Th. Paehge ◽

Th. Sprenkel ◽

K. Wild

Keyword(s):

Traumatic Brain Injury ◽

Botulinum Toxin ◽

Brain Injury ◽

Botulinum Toxin A ◽

Local Application ◽

Toxin A ◽

Enhancing Effect ◽

Severe Spasticity

Download Full-text

Investigating inducible muscle overactivity in acquired brain injury and the impact of Botulinum Toxin A.

Archives of Physical Medicine and Rehabilitation ◽

10.1016/j.apmr.2021.07.802 ◽

2021 ◽

Author(s):

Ian J. Baguley ◽

Hannah L. Barden ◽

Karen Byth

Keyword(s):

Botulinum Toxin ◽

Brain Injury ◽

Botulinum Toxin A ◽

Acquired Brain Injury ◽

Toxin A ◽

The Impact

Download Full-text

Functional outcome following Botulinum toxin A injection to reduce spastic equinus in adults with traumatic brain injury

Brain Injury ◽

10.1080/0269905031000149498 ◽

2004 ◽

Vol 18 (1) ◽

pp. 57-63 ◽

Cited By ~ 38

Author(s):

Jimy Fock ◽

Mary P. Galea ◽

Barry C. Stillman ◽

Barry Rawicki ◽

Malcolm Clark

Keyword(s):

Traumatic Brain Injury ◽

Botulinum Toxin ◽

Brain Injury ◽

Functional Outcome ◽

Botulinum Toxin A ◽

Toxin A

Download Full-text

Onabotulinum Toxin A (Botox) for Spasticity Associated With Multiple Sclerosis

Canadian Journal of Health Technologies ◽

10.51731/cjht.2021.43 ◽

2021 ◽

Vol 1 (3) ◽

Author(s):

Daphne Hui ◽

Charlene Argáez

Keyword(s):

Multiple Sclerosis ◽

Clinical Practice ◽

Botulinum Toxin ◽

Cost Effectiveness ◽

Clinical Practice Guidelines ◽

Practice Guidelines ◽

Evidence Based ◽

Toxin A ◽

Onabotulinum Toxin A

Evidence-based clinical practice guidelines recommend the use of botulinum toxin (which includes onabotulinum toxin A [Botox]) to treat spasticity caused by multiple sclerosis. There is a lack of recent evidence regarding the clinical and cost-effectiveness of Botox as a treatment for spasticity caused by multiple sclerosis; thus, there is a need for well-designed studies on this topic.

Download Full-text